Biography

Professor Michael Arthur is the new President & Provost of UCL and is the first clinical academic to hold this position in the history of the university. He was, until recently, Vice-Chancellor of the University of Leeds (2004–2013) where he is credited with guiding that large comprehensive university to academic excellence in research, innovation and student education, reaching a clear position amongst the top 100 universities in the world (QS ranking).

He is formerly Professor of Medicine (1992–2004), Head of the School of Medicine (1998–2001) and Dean of the Faculty of Medicine, Health and Life Sciences in Southampton (2003–2004). During his tenure the Medical School achieved major growth in its research profile with excellent results in the Research Assessment Exercise 2001 and a maximum score (24/24 points) in the Quality Assurance Exercise of Medical Education.   

Professor Arthur is a hepatologist, with research interests in liver cell biology and the cell and molecular pathogenesis of liver fibrosis, developed initially under the guidance of Monty Bissell at the Liver Center Laboratory, University of California, San Francisco (1986-1988). More recently Professor Arthur was a Fulbright Distinguished Scholar at Mount Sinai School of Medicine in New York (2002) working in Scott Friedman’s laboratory. He was awarded the Linacre medal of the Royal College of Physicians in 1994 and became a Fellow of the Academy of Medical Sciences in 1998.

Professor Arthur has a significant national and international profile in higher education as well as medicine. He was Chair of the Advisory Group for National Specialised Services for the Department of Health (2010–2013) and he is a longstanding member of the Council of the Medical Research Council (2006–current). He is a US/UK Fulbright Commissioner and a former Chair of both the Worldwide Universities Network and the Russell Group of Universities.

Professor Arthur took up his current post on 1 September 2013.

Full biography and CV

National roles

Medical Research Council

  • Council Member (2008–present)

Russell Group

  • Chair (2009–2012)
  • Member (2004–present)

Department of Health

  • Chair of the Advisory Group on National Specialist Services for the NHS (2010–2013)
  • Member of the Advisory Group on Hepatitis (1998–2004)

Higher Education Funding Council for England

  • Chair of the National Student Survey Steering Group (2005–2008)
  • Strategic Research Committee, under the Chairmanship of Sir Gareth Roberts (April 2003–2005)
  • Research Assessment Exercise 2001 Unit of Assessment 3 Panel Member (June 1999–December 2001)

Qualifications and Curriculum Authority

  • Board member (2007–2010)

Department for Education and Skills/Department for Children, Schools and Families

  • Expert advisory group on the new diplomas and the wider 14–19 reform programme (2007–2009)
  • Champion for 14–19 Reform Programme (2006–2007)

Universities UK

  • Board member (2009–2012)
  • Member of Health and Social Care Policy Committee (2008–2009)
  • Member of Research Policy Network (formerly Committee) (2006–present)
  • Member (2004–present)

British Association for the Study of the Liver

  • President (2001–2003)

British Liver Trust

  • Vice-President (2008–present)
  • Chairman of the Board of Trustees (2003–2006)

International roles 

Worldwide Universities Network (WUN)

  • Vice-Chair (2009–2012)
  • Chair (2007–2009)
  • Board Member (2004–2012)

The US–UK Fulbright Commission

  • Commissioner (2008–present)

Grant awards committees

Wellcome Trust
Cell & Molecular Panel member (October 1998–July 2002)
Vice Chairman, Cell and Molecular panel (2000–2001)
Chairman, Cell and Molecular panel (2003–2004)

British Liver Trust
Member of Medical Advisory Committee. Responsibility for assessment of British Liver Trust project grants (February 1993–2001)
Member of the Board of Trustees (2001–2004)

British Digestive Foundation
Representative of BSG on BDF Research Awards Committee. Responsibility for assessment of BSG/BDF Training Fellowships including biannual interview committees (July 1994–July 1997)

South and West Regional Health Authority 
South and West RHA NHS R&D Responsive Committee. Responsibility for assessment of project and small grant submissions (August 1996–August 1998)

Medical Research Council
Invited Panel member and site visit for Edinburgh ‘Centre for Inflammation’ (November 2000)

Medical Research Council and Wellcome Trust
Chairman, Avon Longitudinal Study of Parents and Children (ALSPAC) committee (2003–2005)

Awards and prizes

Fogarty International Travelling Fellowship (1986–1988) and postdoctoral scholar UCSF Liver Center, San Francisco, USA

American Liver Foundation Research Prize (1987) for best abstract submitted by a research fellow to the American Association for the Study of Liver Diseases (AASLD) annual meeting, presented at AASLD, Chicago, USA

Linacre Medal (1994): Royal College of Physicians’ annual award for research achievement under the age of 40, judged on basis of submitted summary and publications

Fulbright Distinguished Scholar Award (2001–2002), to undertake a period of sabbatical leave in the Division of Hepatology, Mount Sinai School of Medicine, New York, USA

Honorary Doctor of Letters (2010), University of Southampton 


Editorships

  • Comparative Hepatology: Editorial Board Member (2002–2004)
  • Journal of Hepatology: Editorial Board Member (December 1999–2004)
  • Journal of Gastroenterology: International Advisory Board Member (January 1998–2004)
  • Hepatology: Editorial Board Member (October 1996–2001)
  • Gut: Associate Editor, responsible for hepatology section (December 1995–December 2001); Editorial Board Member (January 2004–2002)
  • Clinics in Gastroenterology (Baillieres): Editorial Board Member (1992–1998)
  • Clinical Science: Specialist Editor (October 1992–September 1997)

Former appointments

Dean of the Faculty of Medicine, Health and Life Sciences, University of Southampton (2003–2004). Responsible for Schools of Medicine, Biological Sciences, Psychology, Nursing/Midwifery and Allied Health Professions. Member of the University Executive Group.

Fulbright Distinguished Scholar, Mount Sinai School of Medicine, New York, USA (sabbatical leave, March 2002–January 2003). Sabbatical awarded from the University of Southampton in recognition of contribution to the headship of the School of Medicine. Supported by a Fulbright Distinguished Scholar Award.

Director of Research, School of Medicine, University of Southampton (May 2001–December 2002)

Head, School of Medicine, University of Southampton (1998–2001). Post is the equivalent of Dean of Medicine in other universities, with full leadership and budgetary responsibility for the School with an annual turnover of approximately £33 million.

Research Coordinator, School of Medicine, University of Southampton (August 1995–August 1998)

Head, Department of Medicine, University of Southampton (August 1992–August 1998) and Honorary Consultant Physician, Southampton University Hospitals Trust. Specialist interest: Hepatology.

Professor of Medicine, University of Southampton (August 1992–August 2004)

Senior Lecturer in Medicine, Department of Medicine II and Honorary Consultant Physician, Southampton General Hospital (August 1989–July 1992). Appointed under the New Appointment Scheme for Clinical Academics. Specialist interest: Hepatology. 

Fogarty International Research Fellow and Postdoctoral Scholar, University of California San Francisco and Liver Center, San Francisco General Hospital under Professor DM Bissell (September 1986–August 1988)

Lecturer in Medicine, University of Southampton and Honorary Senior Registrar, Southampton General Hospital under Professor R Wright, Hepatology/Gastroenterology/Internal Medicine (November 1982–August 1989). Two years' special leave for International Research Fellowship (September 1986–August 1988).

Research Fellow, Professorial Medical Unit, University of Southampton and Honorary Senior Registrar, Southampton General Hospital under Professor R Wright, Hepatology/Gastroenterology (March–October 1982).

Rotating Registrar in Internal Medicine/Gastroenterology, Wessex Region (1980-1982)

Senior House Officer to Professorial Department of Medicine, University Hospital, Nottingham (August 1978–January 1980)

House Officer posts in Southampton (Medicine) and Portsmouth (Surgery) (1977–1978)


Qualifications and Fellowships

Fellow of the Royal Society for Arts, Commerce, Manufacturers (2006)

Fellow of the Academy of Medical Sciences (1998) 

Fellow of the Royal College of Physicians, UK (April 1993)

Doctor of Medicine, University of Southampton (June 1986) 

Accreditation: Gastroenterology/Internal Medicine (June 1986)

Member of the Royal College of Physicians, UK (June 1979)

Bachelor of Medicine, University of Southampton (June 1977) 

Full original peer reviewed papers

Nattrass M, Arthur MJP, Smythe P, McGill JI, Todd PG, Alberti KGMM.
Hyperlactataemia in diabetics with retinopathy during combined sulphonylurea and phenformin therapy. 
Diabetes & Metabolism, 1978;4:1–4.

Ashworth M, Arthur MJP, Turner AD, Smith PR. 
A comparison of serum concentrations of sulphasalazine and some of its metabolites after therapy by the oral or rectal route. 
Pharmatherapeutica, 1984;3:551–55.

Arthur MJP, Lee A, Wright R. 
Sex differences in the metabolism of ethanol and acetaldehyde in normal subjects. 
Clinical Science, 1984;67:397–401.

Arthur MJP, Tanner AR, Patel C, Wright R, Renwick AG, George CF. 
Pharmacology of propranolol in patients with cirrhosis and portal hypertension. 
Gut, 1985;26:14–19.

Hillier K, Smith CL, Jewell R, Arthur MJP, Ross G. 
Abnormal duodenal mucosa synthesis of prostaglandins in duodenal ulcer disease. 
Gut, 1985;26:237–240.

Arthur MJP, Bentley I, Kowalski Saunders P, Tanner AR, Millward Sadler GH, Wright R. Oxygen derived free radicals promote hepatic injury in the rat. 
Gastroenterology, 1985;89:1114–1122.

Arthur MJP, Kowalski Saunders P, Wright R. 
C parvum elicited hepatic macrophages demonstrate enhanced respiratory burst activity compared with resident Kupffer cells in the rat. 
Gastroenterology, 1986;91:174–181.

Arthur MJP, Kowalski Saunders P, Gurney S, Tolcher R, Bull FG, Wright R. 
Reduction of ferricytochrome C may underestimate superoxide production by monocytes. 
Journal of Immunological Methods, 1987;98:63–69.

Arthur MJP, Kowalski Saunders P, Wright R. 
Effect of endotoxin on release of reactive oxygen intermediates by rat hepatic macrophages. 
Gastroenterology, 1988;95:1588–1594.

Shepherd HA, Royle G, Ross APR, Diba A, Arthur MJP, Colin Jones D. 
Endoscopic biliary endoprosthesis in the palliation of malignant obstruction of the distal common bile duct: a randomized trial. 
British Journal of Surgery, 1988;75:1166–1168.

Arthur MJP, Friedman SL, Roll FJ, Bissell DM. 
Lipocytes from normal rat liver release a neutral metalloproteinase that degrades basement membrane (type IV) collagen. 
Journal of Clinical Investigation, 1989;84:1076–1085.

Friedman SL, Arthur MJP.
Activation of cultured rat hepatic lipocytes by Kupffer cell conditioned medium. Direct enhancement of matrix synthesis and stimulation of cell proliferation via induction of platelet derived growth factor receptors. 
Journal of Clinical Investigation, 1989;84:1780–1785.

Iredale JP, Murphy G, Hembry RM, Friedman SL, Arthur MJP.
Human hepatic lipocytes synthesize tissue inhibitor of metalloproteinases-1 (TIMP-1): Implications for regulation of matrix degradation in liver. 
Journal of Clinical Investigation, 1992;90:282–287.

Kowalski-Saunders P, Winwood PJ, Arthur MJP, Wright R. 
Reversible inhibition of albumin production by rat hepatocytes maintained on a laminin-rich gel in response to secretory products of Kupffer cells and cytokines. 
Hepatology, 1992;16:733–741.

Arthur MJP, Stanley A, Iredale JP, Rafferty JA, Hembry RM, Friedman SL. 
Secretion of 72kDa type IV collagenase/gelatinase by cultured human lipocytes; analysis of gene expression, protein synthesis and proteinase activity. 
Biochemical Journal, 1992;287(3):701–707.

Arany E, Afford S, Strain AJ, Winwood PJ, Arthur MJP, Hill DJ. 
Differential cellular synthesis of insulin-like growth factor binding protein-1 (IGFBP-1) and IGFBP-2 messenger RNAs within human liver. 
J Clin Endocrinol Metabol, 1994;79:1871–1876.

Iredale JP, Goddard S, Murphy G, Benyon RC, Arthur MJP.
Tissue inhibitor of metalloproteinase-1 and interstitial collagenase expression in autoimmune chronic active hepatitis and activated human hepatic lipocytes. 
Clinical Science, 1995;89:75–81.

Winwood PJ, Schuppan D, Iredale JP, Kawser CA, Docherty AJP, Arthur MJP.
Kupffer cell-derived 95kDa type IV collagenase/gelatinase B: Characterisation and expression in cultured cells. 
Hepatology, 1995;22:304–315.

Vyas SK, Leyland H, Gentry J, Arthur MJP. 
Transin (stromelysin) is expressed in early rat lipocyte primary culture. 
Gastroenterology, 1995;109:889–898.

Benyon RC, Iredale JP, Goddard S, Winwood PJ, Arthur MJP. ­ 
Increased expression of tissue inhibitor of metalloproteinases-1 and -2 relative to interstitial collagenase in fibrotic human liver. 
Gastroenterology, 1996;110(3):821–831.

Aston KE, Stamouli A, Thomas EJ, Vyas SK, Iredale JP, Arthur MJP, Richardson MC. 
Effect of gonadotrophin on cell and matrix retention and expression of metalloproteinases and their inhibitor in cultured human granulosa cells modelling corpus luteum function. 
Molecular Human Reproduction, 1996;2:26–30.

Herbert C, Arthur MJP, Robinson C. 
Augmentation by eosinophils of gelatinase activity in the airway mucosa: comparative effects as a putative mediator of epithelial injury. 
Br J Pharmacol, 1996;117:667–674.

Iredale JP, Benyon RC, Arthur MJP, Ferris W, Alcolado R, Winwood P, Clark N, Murphy G. 
TIMP-1 expression is enhanced relative to interstitial collagenase in experimental liver injury and fibrosis. 
Hepatology, 1996;24:176–184.

Leyland H, Gentry J, Arthur MJP, Benyon RC. 
The plasminogen activating system in hepatic stellate cells. 
Hepatology, 1996;24:1172–1178.

Jenkins SA, Kingsnorth AN, Davies M, Elias E, Turnbull AJ Bassendine MF, James OFW, Iredale JP, Vyas S, Arthur MJP, Kendall F, Shields R. 
A multicentre randomised controlled trial comparing the efficacy of Octreotide and injection sclerotherapy in the management of the acute variceal bleed. 
Gut, 1997;41:526–534.

Kawser CA, Iredale JP, Winwood PJ, Arthur MJP. 
Rat hepatic stellate cell expression of alpha-2-macroglobulin is a feature of cellular activation (implications for matrix remodelling in hepatic fibrosis). 
Clinical Science, 1998;95:179–186.

Thomson RK, Davis Z, Palmer JM, Arthur MJP, Yeaman SJ, Chapman CJ, Spellerberg MB, Stevenson FK. 
Immunogenetic analysis of a panel of monoclonal IgG and IgM anti-pyruvate dehydrogenase complex antibodies derived from patients with primary biliary cirrhosis. 
Journal of Hepatology, 1998;28:582–594.

Iredale JP, Benyon RC, Pickering J, McCullen M, Northrop M, Pawley S, Hovell C, Arthur MJP.
Mechanisms of spontaneous resolution of rat liver fibrosis: Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. 
Journal of Clinical Investigation, 1998;102:538–549.

Thompson KC, Fowell A, Trowern A, Maneke M, Haycock C, Gentry J, Arthur MJP, Sheron N. 
Primary rat and mouse hepatic stellate cells express the macrophage inhibitor cytokine interleukin 10 during the course of activation in vitro. 
Hepatology, 1998;28:1518–1524.

Bahr MJ, Vincent KJ, Arthur MJP, Fowler AV, Smart DE, Wright MC, Clark IM, Benyon RC, Iredale JP, Mann DA. Control of the tissue inhibitor of metalloproteinases-1 promoter in culture-activated rat hepatic stellate cells: regulation by activator protein-1 DNA binding proteins. 
Hepatology, 1999;29:839–848.

Gaca MDA, Pickering JA, Arthur MJP, Benyon RC. Human and rat hepatic stellate cells produce stem cell factor: a possible mechanism for mast cell recruitment in liver fibrosis. 
Journal of Hepatology, 1999;39:850–858.

Elsharkawy AM, Wright MC, Hay RT, Arthur MJP, Hughes T, Bahr MJ, Degitz K, Mann DA. 
Persistent activation of nuclear factor-KB in cultured rat hepatic stellate cells involves the induction of potentially novel rel-like factors and prolonged changes in the expression of IkB family proteins. 
Hepatology, 1999;30:761–769.

Benyon RC, Hovell CH, Gaca M, Jones E, Iredale JP, Arthur MJP. 
Progelatinase A is produced and activated by rat hepatic stellate cells and promotes their proliferation. 
Hepatology, 1999;30:977–986.

Williams EJ, Gaca MDA, Brigstock DR, Arthur MJP, Benyon RC. 
Increased expression of connective tissue growth factor in fibrotic human liver and in activated hepatic stellate cells. 
Journal of Hepatology, 2000; 32: 754–761.

Trim JE, Samra SK, Arthur MJP, Wright MC, McAulay M, Beri R, Mann DA. 
Upstream tissue inhibitor of metalloproteinases-1 (TIMP-1) element-1, a novel and essential regulator DNA motif in the human TIMP-1 gene promoter, directly interacts with a 30-kDa nuclear protein. 
Journal of Biological Chemistry, 2000;275(9):6657–6663.

Issa R, Williams E, Trim N, Kendall T, Arthur MJP, Reichen J, Benyon RC, Iredale JP. 
Apoptosis of hepatic stellate cells: involvement in resolution of biliary fibrosis and regulation by soluble growth factors. 
Gut, 2001;48(4):548–557.

Smart DE, Vincent KJ, Arthur MJP, Eickelberg O, Castellazzi M, Mann J, Mann DA. 
JunD Regulates transcription of the tissue Inhibitor of Metalloproteinases-1 and Interleukin-6 Genes in Activated Stellate Cells. 
Journal of Biological Chemistry, 2001;276(26):24414–24421.

Wright MC, Issa R, Smart DE, Trim N, Murray GI, Primrose JN, Arthur MJP, Iredale JP, Mann DA. 
Gliotoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats. 
Gastroenterology, 2001;121:685–698.

Williams EJ, Benyon RC, Trim N, Hadwin R, Grove B, Arthur MJP, Unemori E, Iredale JP. 
Relaxin inhibits effective collagen deposition by cultured hepatic stellate cells and decreases rat liver fibrosis in vivo. 
Gut, 2001; 49: 577–583.

Vincent KJ, Jones E, Arthur MJP, Smart D, Trim J, Wright M, Mann DA. 
Regulation of E-box DNA binding during in vivo and in vitro activation of rat and human hepatic stellate cells. 
Gut, 2001; 49: 713–719.

Murphy FR, Issa R, Zhou X, Rhatnarajah S, Nagase H, Arthur MJ, Benyon C, Iredale JP 
Inhibition of apoptosis of activated hepatic stellate cells by TIMP-1 is mediated via effects on MMP inhibition: Implications for reversibility of liver fibrosis. 
Journal of Biological Chemistry, 2002; 277: 11069–76.

Gao R, McCormick CJ, Arthur MJP, Ruddell R, Oakley F, Smart DE, Murphy FR, Harris MPG, Mann DA. 
High efficiency gene transfer into cultured primary rat and human hepatic stellate cells using baculovirus vectors. 
Liver, 2002;22:15–22.

Schiedermaier P, Harrison P, Arthur M, Grandt D, Sutton R, Drewe J, Larsen F, Sieber C; European Lanreotide Study Group.Effect of the somatostatin analogue lanreotide on meal-stimulated portal blood flow in patients with liver cirrhosis 
Digestion, 2002;65(1):56–60.

Murphy F, Waung J, Collins J, Arthur MJ, Nagase H, Mann D, Benyon RC, Iredale JP. 
N-Cadherin cleavage during activated hepatic stellate cell apoptosis is inhibited by tissue inhibitor of metalloproteinase-1. 
Comparative Hepatology, 2004 Jan 14;3 Suppl 1:S8.

Bertrand-Philippe M, Ruddell RG, Arthur MJ, Thomas J, Mungalsingh N, Mann DA. 
Regulation of Tissue Inhibitor of Metalloproteinase 1 Gene Transcription by RUNX1 and RUNX2 
Journal of Biological Chemistry, 2004 Jun 4;279(23):24530–9.

Reeves HL, Narla G, Ogunbiyi O, Haq AI, Katz A, Benzeno S, Hod E, Harpaz N, Goldberg S, Tal-Kremer S, Eng FJ, Arthur MJ, Martignetti JA, Friedman SL. 
Kruppel-like factor 6 (KLF6) is a tumor-suppressor gene frequently inactivated in colorectal cancer. 
Gastroenterology, 2004 Apr;126(4):1090–103.

Zhou X, Hovell CJ, Pawley S, Hutchings MI, Arthur MJP, Iredale JP, Benyon RC 
Expression of matrix metalloproteinase-2 and -14 persists during early resolution of experimental liver fibrosis and might contribute to fibrolysis 
Liver International, 2004; 24: 1–10.

Takahara T., Smart DE., Arthur MJP., Oakley F., and Mann DA.
MMP-9 gene transcription is induced in myofibroblasts cultured in 3-D collagen I gels: regulation by NF-kB, AP1 and Sp1. 
International Journal of Biochemistry and Cell Biology, 2004; 36: 353–63.

Issa R, Zhou X, Constandinou CM, Fallowfield J, Millward-Sadler H, Gaca MD, Sands E, Suliman I, Trim N, Knorr A, Arthur MJ, Benyon RC, Iredale JP.
Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking. 
Gastroenterology, 2004; 126(7):1795–808.

Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, Hubscher S, Roskams T, Pinzani M, Arthur MJ.
European Liver Fibrosis Group. Serum markers detect the presence of liver fibrosis: a cohort study. 
Gastroenterology, 2004 Dec;127(6):1704–13.

Xu L, Hui AY, Albanis E, Arthur MJ, O'Byrne SM, Blaner WS, Mukherjee P, Friedman SL, Eng FJ.
Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. 
Gut, 2005 Jan;54(1):142–51.

Invited academic lectures

Matrix degradation in the liver. American Association for the Study of Liver Diseases (AASLD), Spring conference on Connective Tissue Biology of the Liver. Asilomar, California, USA (April 1989)

State of the art lecture: Mechanisms of liver cell injury. British Society of Gastroenterology, Dublin, Ireland (September 1989)

Type IV collagenase, hepatic lipocytes and liver fibrosis. British Connective Tissue Society, Manchester, UK (March 1990)

Recent advances in viral hepatitis. Primary Care Section of the British Society of Gastroenterology, Southampton, UK (September 1990)

The Metalloproteinases. International conference on Cellular and Molecular Bases of Liver Cirrhosis, INSERM, Rennes, France (July 1991)

The role of matrix degradation in liver fibrosis. International conference on Molecular and Cell Biology of Liver Fibrogenesis, German Association for the Study of the Liver, Marburg, Germany (January 1992)

Matrix metalloproteinases, their inhibitors and role in liver fibrosis. European Cellular Pathology Course, Lyon, France (September 1992)

Matrix degradation in the liver. Falk Symposium No. 71, Fat Storing Cells and Liver Fibrosis, Florence, Italy (July 1993)

Mechanisms of fibrosis in alcoholic liver disease. British Liver Trust/Royal College of Physicians joint conference, London, UK (December 1993)

Collagenases and liver fibrosis degradation. Association Francaise de l'Etude du Foie (AFEF) seminar on liver fibrosis, Eurodisney, France (January 1994)

Pathogenic mechanisms and treatment prospects in liver fibrosis. Royal College of Physicians Advanced Medicine Course, London (February 1994)

Progress in liver fibrosis. 7th International Symposium on Cells of the Hepatic Sinusoid, Kyoto, Japan (September 1994)

Meet the Professor luncheon, Liver Fibrogenesis. AASLD, Chicago, USA (November 1994)

Hepatic fibrosis. Advances in Paediatric Hepatology, London (January 1995)

State of the Art Lecture: Matrix degradation in the liver. VIIth Belgian Week of Gastroenterology, Knokke, Belgium (March 1995)

Mechanisms of fibrosis and matrix degradation. ESPGAN Hepatology Summer School, Wilsede, Germany (July 1995)

The role of matrix degradation in liver fibrosis. The Linacre Lecture. Royal College of Physicians Regional Conference, Sheffield (September 1995)

Modern concepts of hepatic fibrogenesis. 4th United European Gastroenterology Week, Berlin, Germany (September 1995)

Matrix proteinases in liver growth and repair. Early Morning Workshop Moderator AASLD, Chicago, USA (November 1995)

Iron overload and liver fibrosis. Festschrift for June Halliday, Brisbane, Australia (November 1995)

'Can we prevent cirrhosis?':State of the Art Lecture. Jaundice in Paradise meeting, Brisbane, Australia (November 1995)

Collagen degradation. International Association for the Study of the Liver, Symposium on Liver Fibrosis, Cape Town (February 1996)

Prevention of progression of liver disease. Institute of Liver Studies 30th Anniversary Scientific Meeting, King's College London, UK (April 1996)

New treatments for liver fibrosis. British Society of Gastroenterology Liver Symposium, Manchester (September 1996)

Mechanisms of fibrosis and matrix degradation. United European Gastroenterology Week ESPGAN Postgraduate Course, Paris (November 1996)

The role of metalloproteinases and their inhibitors in liver fibrosis. Japanese Society for Liver Cell Biology, Tokyo (June 1997)

State of the Art Lecture: Liver Fibrogenesis. United European Gastroenterology Week, Birmingham (October 1997)

The pathogenesis of liver fibrosis: A role for altered matrix degradation. 45th Japan Matrix Club, Akita (April 1998)

Alcoholic Liver Disease. Royal College of Physicians Regional Lecture, Taunton (June 1998)

Role of TIMPs in liver fibrosis. NIH (NIAAA) Conference on Alcoholic Liver Disease: Pathogenesis and Mechanisms, South Carolina, USA (June 1998)

Fibrosis and altered matrix degradation. World Congress of Gastroenterology, Vienna, Austria (September 1998)

Future expectations for academic medicine. BMA Conference of Medical Academic Representatives, London (June 1999)

Liver fibrosis. Canadian Association of the Study of the Liver, Kananaskis, Alberta, Canada (October 1999)

Liver fibrosis. Royal College of Physicians/Medical Research Society conference, London (November 1999)

Liver fibrosis. European Association for Gastroenterology and Endoscopy (EAGE) Postgraduate Course, Rome, Italy (November 1999)

Liver Cirrhosis. 11th Yamaguchi Symposium, Yamaguchi, Japan (December 1999)

Matrix metalloproteinases and their inhibitors in liver fibrogenesis. Falk Workshop on Chronic Hepatitis: New Concepts of Pathogenesis, Diagnosis, and Treatment, Cologne, Germany (January 2000)

Liver fibrosis. European Meeting on Biomarkers of Organ Damage and Dysfunction (EMBODY), Cambridge, UK (April 2000)

TIMPs in fibrosis. AASLD Single Topic Conference on Mechanisms and Therapy of Hepatic Fibrosis, Virginia, USA (June 2000)

Fibrosis. United European Gastroenterology Week (UEGW), Brussels, Belgium. (November 2000)

Hepatic fibrosis. 5th Advanced Course on Gastroenterology & Hepatology, Royal College of Physicians, Edinburgh (January 2001)

New developments in liver fibrosis. Opening of the Henry Wellcome Laboratory for Molecular & Cellular Gastroenterology, Royal Liverpool Hospital, UK (February 2001)

Hepatic stellate cells, matrix degradation and liver fibrosis. Honeyman Gillespie Lecture, University of Edinburgh (February 2001)

Stellate and macrophage cooperation leading to hepatic fibrosis. 11th Nikolas Symposium, Athens, Greece (May 2001)

The role of TIMPs in the progression and regression of liver fibrosis: TIMP-1 gene regulation in hepatic stellate cells. New Strategies for the Treatment of Liver Cirrhosis, Tokyo, Japan (June 2001)

Liver fibrosis: from cell and molecular pathogenesis to clinical hepatology. Invited lecture, Toyama, Japan (June 2001)

The role of TIMPs in the progression and regression of liver fibrosis. Division of Hepatology invited seminar series, Mount Sinai School of Medicine, New York, USA (2001)

Mechanisms of the progression and regression of carbon tetrachloride-induced liver injury, UNC/NIH conference on Mechanisms of Tissue Injury and Repair in the Gut and Liver, Raleigh, Durham, USA (May 2002)

Mechanisms of Reversibilty of Liver Fibrosis. GI and Hepatology Grand Rounds, Duke University, North Carolina, USA (September 2002)

Liver Fibrosis: Prospects for Treatment, Meet the Professor Lunch AASLD, Boston, USA (2002)

Liver Fibrosis Update. Moderator for AASLD breakfast session on Advances in Liver Fibrosis, Boston, USA (2002)

Screening for Cirrhosis: AASLD Clinical Research Workshop, Orlando (May 2003)

Reversibility of Cirrhosis: A new Frontier. Current Topics in Gastroenterology - International Meeting, Faro, Portugal (June 2003)

Matrix Degradation in the Liver – Update. American Society for Investigative Pathology, Washington DC, USA (May 2004)

The National Student Survey – A National Treasure

(i) HEFCE sponsored open meeting for the sector, Royal College of Physicians (London 2006)

(ii) Higher Education Academy annual conference, Birmingham (2007)

(iii) Student Experience Conference, HEFCE/UUK sponsored, London (2007)

(iv) Marketing Managers' Forum, University of Greenwich (2007)

(v) Annual press conferences (2006, 2007)

Leading a transformational strategic change programme at the University of Leeds

(i) Taking charge of our future. The American Council on Education’s 90th Annual Meeting, San Diego, USA (February 2008)

(ii) Balanced Scorecard Collaborative meeting, Washington DC, USA (March 2009)

(iii) Invited talk to leadership conference, University of Western Australia (April 2009).

Published proceedings

Tanner AR, Keyhani A, Arthur MJP, Wright R. 
Evidence for a sequence of macrophage activation. 
In: Sinusoidal Liver Cells. (eds) Knook DL, Wisse E. Elsevier/North Holland. 1982;405–412.

Arthur MJP, Kowalski Saunders P, Wright R. 
A comparison of the respiratory burst activity of resident Kupffer cells with C parvum elicited hepatic macrophages. 
In: Cells of the Hepatic Sinusoid. (eds) Kirn A, Knook DL, Wisse E. Kupffer Cell Foundation, Rijswijk, The Netherlands. 1986;1:59–64.

Arthur MJP, Friedman SL, Bissell DM. 
Gelatinase secretion by hepatic lipocytes. 
In: Cells of the Hepatic Sinusoid. (eds) Wisse E, Knook DL, Decker K. Kupffer Cell Foundation, Rijswijk, The Netherlands. 1989;2:57–60.

Kowalski Saunders P, Arthur MJP, Wright R. 
Inhibition of hepatocyte albumin synthesis, but not total protein synthesis, by a soluble factor derived from liver macrophages. 
In: Cells of the Hepatic Sinusoid. (eds) Wisse E, Knook DL, Decker K. Kupffer Cell Foundation, Rijswijk, The Netherlands. 1989;2:255–256.

Kowalski Saunders P, Arthur MJP, Wright R. 
Effects of cytokines and Kupffer cell soluble products on primary cultures of hepatocytes maintained on extracellular matrix. 
In: Cells of the Hepatic Sinusoid. (eds) Wisse E, Knook DL, McCuskey RS. Kupffer Cell Foundation, Rijswijk, The Netherlands. 1991;3:64–67.

Arthur MJP, Jackson CL, Friedman SL. 
Release of type IV collagenase by human lipocytes. 
In: Cells of the Hepatic Sinusoid. (eds) Wisse E, Knook DL, McCuskey RS. Kupffer Cell Foundation, Rijswijk, The Netherlands. 1991;3:161–163.

Winwood PJ, Kowalski-Saunders P, Green I, Murphy G, Hembry RM, Arthur MJP.
Kupffer cells release a 95kD gelatinase. 
In: Cellular and Molecular Bases of Liver Cirrhosis. (eds) Clément B, Guillouzo A. Colloque INSERM/John Libbey Eurotext Ltd. 1992;216:307–310.

Iredale JP, Winwood PJ, Choudhury AK, Hembry RM, Murphy G, Arthur MJP.
Lipocyte proliferation in the C. parvum model of macrophage-induced liver injury is associated with expression of 72kDa type IV collagenase/gelatinase. 
In: Cells of the Hepatic Sinusoid. (eds) Knook DL, Wisse E. Leiden: The Kupffer Cell Foundation. 1993;4:105–108.

Winwood PJ, Green I, Hembry RM, Murphy G, Strain A, Arthur MJP. 
Release of 95kD type IV collagenase/gelatinase by human Kupffer cells and its expression in diseased human liver. 
In: Cells of the Hepatic Sinusoid. (eds) Knook DL, Wisse E. Leiden: The Kupffer Cell Foundation. 1993;4:301–303.

Choudhury AK, Kowalski-Saunders PWJ, Arthur MJP.
Dynamic studies of the effect of Kupffer cell conditioned media and recombinant cytokines on a2-macroglobulin secretion by rat hepatocytes cultured on a basement membrane-like substratum. 
In: Cells of the Hepatic Sinusoid. (eds) Knook DL, Wisse E. Leiden: The Kupffer Cell Foundation. 1993;4:53–55.

Vyas SK, Leyland H, Gentry J, Arthur MJP.
Transin (rat stromelysin) expression by hepatic lipocytes in early primary culture: analysis of gene transcription, protein activity and immunolocalization. 
In: Cells of the Hepatic Sinusoid. (eds) Wisse E, Knook DL, Wake K. Leiden: Kupffer Cell Foundation, 1995, 396–399.

Iredale JP, Benyon RC, Ferris WF, Cottrell B, Alcolado R, Murphy G, Arthur MJP.
Tissue inhibitor of metalloproteinase-1 expression is up-regulated relative to interstitial collagenase in CCl4 induced liver fibrosis and activated human hepatic lipocytes. 
In: Cells of the Hepatic Sinusoid. (eds) Wisse E, Knook DL, Wake K. Leiden: Kupffer Cell Foundation, 1995, 418–419.

Arthur MJP.
Mechanisms of fibrosis and matrix degradation. 
United European Gastroenterology Week, Paris (November 1996)

Bahr MJ, Clark IM, Edwards DR, Iredale JP, Arthur MJP, Mann DA. 
Mapping of trans-activating regions of the human TIMP-1 promoter in freshly isolated and culture activated hepatic stellate cells. 
In: Cells of the Hepatic Sinusoid, Vol. 6. (eds) Wisse E, Knook DL, Balabaud C. Leiden: Kupffer Cell Foundation. 1997, 18–21.

Benyon RC, Pickering JP, Arthur MJP.
Hepatic stellate cells produce stem cell factor: A potential mechanism of mast cell recruitment in liver fibrosis. 
In: Cells of the Hepatic Sinusoid, Vol. 6. (eds) Wisse E, Knook DL, Balabaud C. Leiden: Kupffer Cell Foundation. 1997, 26–27.

Hovell CJ, Benyon RC, Gentry JG, Arthur MJP. 
Membrane type matrix metalloproteinase expression correlates with gelatinase A activation in cultured rat hepatic stellate cells. 
In: Cells of the Hepatic Sinusoid, Vol. 6. (eds) Wisse E, Knook DL, Balabaud C. Leiden: Kupffer Cell Foundation. 1997, 44–45.

Benyon RC, Hutchings M, Hovell CJ, Gaca MDA, Jones EH, Arthur MJP.
Regulation of the synthesis and activation of gelatinase A by hepatic stellate cells and its contribution to cell proliferation. 
In: Cells of the Hepatic Sinusoid, Vol. 7. (eds) Wisse E, Knook DL, Fraser R. Leiden: Kupffer Cell Foundation 1999, 161–163.

Elsharkawy A, Arthur MJP, Hay RT, Wright MC, Mann DA. 
Regulation and Function of nuclear factor Kappa B (NF-kB) during culture induced transdifferentiation of rat hepatic stellate cells. 
In: Cells of the Hepatic Sinusoid, Vol 7. (eds) Wisse E, Knook DL, Fraser R. Leiden: Kupffer Cell Foundation 1999, 155–156.

Vincent KJ, Arthur MJP, Mann DA. 
Expression and characterization of basic Helix-Loop-Helix proteins in hepatic stellate cells. 
In: Cells of the Hepatic Sinusoid, Vol. 7. (eds) Wisse E, Knook DL, Fraser R. Leiden: Kupffer Cell Foundation 1999, 15–16.

Arthur MJP. 
Mechanisms of progression and regression of liver fibrosis. 
In: Frontiers in Hepatology 3/ Liver Cirrhosis. (ed) Okita K. Springer-Verlag: Tokyo. 2001, 1–9.

Gaca MDA, Arthur MJP, Benyon RC. 
Proteinase activated receptor-2 is an intermediary for hepatic stellate cell activation by tryptase. 
In: Cells of the Hepatic Sinusoid, Vol. 8. Leiden: Kupffer Cell Foundation, 2001, 269–270.

Williams EJ, Cochrane BC, Arthur MJP, Benyon RC. 
Activation of TGF-β1 by HSC in vitro and consequences for cell proliferation and survival.
In: Cells of the Hepatic Sinusoid, Vol. 8. Leiden: Kupffer Cell Foundation, 2001, 191–194.

Wright MC, Smart DE, McCrudden PR, Trim JE, Primrose JN, Arthur MJP, Mann DA. 
Activators of the PXR prevent the trans-differentiation of human hepatic stellate cells. 
In: Cells of the Hepatic Sinusoid, Vol. 8. Leiden: Kupffer Cell Foundation, 2001, 264–265.

Wright MC, Issa R, Smart DE, Trim N, Primrose JN, Arthur MJP, Iredale JP, Mann DA.
Gliotoxin stimulates the apoptosis of hepatic stellate cells: A mechanism for modulating liver fibrosis. 
In: Cells of the Hepatic Sinusoid, Vol. 8. Leiden: Kupffer Cell Foundation, 2001, 287–290.

Zhou X, Issa R, McCrudden R, Hovell CJ, Arthur MJP, Iredale JP, Benyon RC. 
Expression and activation of gelatinase A in liver fibrosis.
In: Cells of the Hepatic Sinusoid, Vol. 8. Leiden: Kupffer Cell Foundation, 2001, 236–237.

Adams PC, Arthur MJ, Boyer TD, DeLeve LD, Di Bisceglie AM, Hall M, Levin TR, Provenzale D, Seeff L. 
Screening in liver disease: report of an AASLD clinical workshop. Hepatology. 2004 May;39(5):1204–12.

Arthur MJP, Hall AJ, Wright R. 
Hepatitis B, hepatocellular carcinoma, and strategies for prevention. 
Lancet, 1984;i:607–10.

Tanner AR, Arthur MJP, Wright R. 
Macrophage activation, chronic inflammation and gastrointestinal disease. 
Gut, 1984;25:760–84.

Arthur MJP. 
The liver reticuloendothelial system. 
Current Opinion in Gastroenterology, 1986;2:482–488.

Arthur MJP. 
Reactive oxygen intermediates and liver injury. 
Journal of Hepatology, 1988;6:125–131.

Arthur MJP. 
Matrix degradation in the liver. 
Seminars in Liver Disease, 1990;10:47–55.

Arthur MJP.
Autoimmune and drug induced Chronic Active Hepatitis. 
Medicine International, 1990;84:3461–65.

Arthur MJP.
The metalloproteinases. 
In: Cellular and Molecular Aspects of Cirrhosis. (eds) Clément B, Guillouzo A. Colloque INSERM/John Libbey Eurotext, France. 1991;216:235–244.

Arthur MJP.
The role of matrix degradation in liver fibrosis. 
In: Molecular and Cell Biology of Liver Fibrogenesis. (eds) Gressner AM, Ramadori G. Dordrecht: Kluwer Academic Publishers. 1992, Chapter 28, 213–227.

Winwood PJ, Arthur MJP.
Kupffer cells: Their activation and role in animal models of liver injury and human liver disease. 
Seminars in Liver Disease, 1993;13(1):50–59.

Arthur MJP.
Matrix degradation in the liver. 
In: Fat Storing Cells and Liver Fibrosis. (eds) Surrenti C, Casini A, Milani S, Pinzani M. Dordrecht: Kluwer Academic Publishers. 1994, 110–127.

Arthur MJP, Iredale JP. 
Hepatic lipocytes, TIMP-1 and liver fibrosis. 
Journal of the Royal College of Physicians of London. 1994;28:200–208.

Arthur MJP.
Degradation of matrix proteins in liver fibrosis. 
Pathology – Research Practice. 1994;190:825–833.

Arthur MJP.
Autoimmune and drug-induced chronic active hepatitis. 
Medicine International, 1994;22(12):472–476.

Hovell CJ, Arthur MJP. 
The jaundiced adult. 
GP Medicine, 1994;Sept 16:31–32.

Iredale JP, Arthur MJP.
Hepatocyte-matrix interactions. 
Gut, 1994;35:729–732.

Arthur MJP.
Collagenases and liver fibrosis. 
Journal of Hepatology, 1995;22(Suppl. 2):43–48.

Arthur MJP.
Progress in liver fibrosis. 
In: Cells of the Hepatic Sinusoid, Vol. 5. (eds) E Wisse, DL Knook, K Wake. Kupffer Cell Foundation: Leiden, 1995, 372–376.

Arthur MJP.
Pathogenic mechanisms and treatment prospects in liver fibrosis. 
In: Horizons in Medicine, No. 6. ed ST Holgate. Blackwell Science: London, 1995, 87–103.

Arthur MJP.
Pathogenesis, experimental manipulation and treatment of liver fibrosis. 
Experimental Nephrology, 1995;3:90–95.

Arthur MJP.
The role of Ito cells in the degradation of matrix in liver. 
Journal of Gastroenterology and Hepatology, 1995;10:S57–S62.

Arthur MJP.
Ito cell or 'activated liver myofibroblast'?: Toxicology Elsewhere – Comment. 
Human & Experimental Toxicology, 1996;15:175–182.

Arthur MJP.
Tadpoles and the badge of cowardice: A summary of an inaugural lecture. 
Southampton Health Journal, 1996;12:31–34.

Arthur MJP.
Iron overload and liver fibrosis. 
Journal of Gastroenterology and Hepatology, 1996;11:1124–1129.

Alcolado R, Arthur MJP, Iredale JP. 
Pathogenesis of liver fibrosis. 
Clinical Science, 1997;92:103–112.

Arthur MJP.
Matrix degradation in liver: a role in injury and repair. 
Hepatology, 1997;26:1069–1071.

Arthur MJP, Mann DA, Iredale JP. 
Tissue inhibitors of metalloproteinases, hepatic stellate cells and liver fibrosis. 
Journal of Gastroenterology and Hepatology, 1998;13(Suppl):S33–S38.

Arthur MJP.
The cellular and molecular pathogenesis of liver fibrosis. 
Current Medical Literature - Gastroenterology, 1998;17:3–8.

Benyon RC, Arthur MJP.
Mechanisms of hepatic fibrosis. 
Journal of Pediatric Gastroenterology and Nutrition, 1998;27(1):75–85.

Arthur MJP, Benyon RC, Mann DA, Iredale JP. 
The pathogenesis of liver fibrosis: A role for altered matrix degradation. 
Connective Tissue, 1998;30:233–238.

Arthur MJP.
Fibrosis and altered matrix degradation. 
Digestion, 1998;59:376–380.

Arthur MJP, Iredale JP, Mann DA. 
Tissue inhibitors of metalloproteinases: Role in Liver fibrosis and alcoholic liver disease. 
Alcoholism: Clinical and Experimental Research, 1999;23:940–943.

Arthur MJP. 
Autoimmune hepatitis. 
Medicine International, 1999;27(1):52–56.

Thomson RK, Arthur MJP. 
Mechanisms of liver cell damage and repair. 
European Journal of Gastroenterology & Hepatology, 1999;11(9):949–955.

Arthur MJP.
Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis.
American Journal of Physiology – Gastrointestinal and Liver Physiology, 2000;279:G245–G249.

Benyon RC, Arthur MJP.
Extracellular Matrix Degradation and the Role of Hepatic Stellate Cells. 
Seminars in Liver Disease, 2001; 21: 373–384.

Williams E, Arthur MJP.
Liver Fibrosis: An Update 
Current Medical Literature – Gastroenterology, 2002: 1-4.

Arthur MJP.
Autoimmune hepatitis.
Medicine International, 2002; 30: 53–56.

Friedman SL, Arthur MJP.
Reversibility of Liver Fibrosis and Cirrhosis 
Science in Medicine, 2002; Aug:192–203.

Murphy F, Arthur MJP, Iredale JP. 
Developing strategies for liver fibrosis treatment 
Expert Opinion on Investigational Drugs, 2002: 11; 1575–1585.

Chapters in books

Arthur MJP, Wright R.
‘The medical management of bleeding varices’ 
In: Liver and Biliary Surgery (ed) Blumgart L. Churchill Livingstone, London, 1988, Chapter 104, 1345–1355.

Lavine J, Bull G, Millward Sadler GH, Arthur MJP. 
‘Acute viral hepatitis’ 
In: Wright’s Textbook of Liver and Biliary Disease (eds) Millward-Sadler GH, Wright R, Arthur MJP. London: Bailliere Tindall. 1992, 679–786.

Friedman SL, Millward Sadler GH, Arthur MJP.
‘Liver Fibrosis and Cirrhosis’
In: Wright’s Textbook of Liver and Biliary Disease (eds) Millward-Sadler GH, Wright R, Arthur MJP. London: Bailliere Tindall. 1992, 821–881.

Winwood PJ, Arthur MJP.
‘Kupffer cells and endothelial cells’
In: Liver Growth and Repair (eds) Strain AJ, Diehly AM. London: Chapman & Hall. 1998, 482–501.

Vyas SK, Arthur MJP.
‘Hepatobiliary and pancreatic disease’ 
In: Drug Therapy in Old Age (eds) George CF, Woodhouse K. Chichester: John Wiley & Sons. 1998, 487–509.

Arthur MJP.
‘Mechanisms of liver fibrosis’ 
In: New Horizons in Gastrointestinal and Liver Disease: Mechanisms and Management (eds) Farthing MJG, Bianchi-Porro G. Paris: John Libbey Eurotext. 1999, 143–151.

Arthur MJP
‘The role of tissue inhibitors of metalloproteinases (TIMPs) in the pathogenesis of liver fibrosis’
In: Chronic Hepatitis: New concepts of pathogenesis, diagnosis and treatment (eds) Dienes HP, Schirmacher P, Brechot C, Okuda K. Kluwer Academic Publishers: Dordrecht, 2000, 176–182.


Editorials (invited)

Arthur MJP. 
‘Matrix degradation in liver: A role in injury and repair.’
Hepatology, 1997;26:1069–1071.

Arthur MJP
‘Reversibility of liver fibrosis and cirrhosis following treatment of hepatitis C’
Gastroenterology, 2002; 122:1525–1528.


Professional publications

Arthur MJP, Alberti KGMM.
Training in academic medicine: a way forward for the new millennium. 
Journal of the Royal College of Physicians of London, 1999;33(4):359–364.

Arthur MJP
Clinical academic trainees – In response. 
Journal of the Royal College of Physicians of London, 2000;34:503–504.


Reports

Report of a Joint Working Group of the British Society of Gastroenterology, the Research Unit of the Royal College of Physicians of London and the Audit Unit of the Royal College of Surgeons of England.

Guidelines for good practice in and audit of the management of upper gastrointestinal haemorrhage.

Journal of the Royal College of Physicians of London, 1992;26:281–289.


Letters

Arthur MJP, Hanley SP, Clark A. 
Electrical alternans. 
Acta Medica Scandinavica, 1979;206:333–335.

Arthur MJP, Tanner AR, Patel C, George CF, Wright R. 
Propranolol, portal hypertension and hepatic encephalopathy. 
Lancet, 1982;ii:879.


Case reports

Iredale JP, Ridings P, McGinn FP, Arthur MJP. 
Idiopathic and familial colonic varices. 
Gut, 1992;33(9):1285–1288.

Iredale JP, Sterling G, Arthur MJP.
Pancreatitis in a patient with AIDS. 
Endoscopy, 1993;25:25–26.

Hacking CN, Sanderson AJ, Arthur MJP.
Budd-Chiari Syndrome (BCS) – Treatment with transjugular intrahepatic portosystemic stent shunt (TIPSS). 
Journal of Vascular and Interventional Radiology, 1994;9:121–124.

Roseveare CD, Van Heel DA, Lawrence RJ, Arthur MJP.
Helicobacter pylori: Beware blind eradication! 
Gut, 1998;42:757.

Tharakan J, Hossenbocus A, Arthur MJP.
Macromolecular aspartate aminotransferase. 
European Journal of Gastroenterology & Hepatology, 1998;10:4–5.


Patents

Gil JC, Volker M, Becka M, Kroll W, Knorr A, Unger S, Gehrmann M, Hennig G, Burchardt E-R, Arthur MJP, Burt AD, Pinzani M, Schuppan D.
Assessment of liver fibrosis scoring with serum marker algorithms. Patent No. MST2328.


Press articles

Arthur MJP.
The National Student Survey, Sunday Times Good University Guide 2006.

Arthur MJP, Hopkin D.
Science education and the 14–19 reforms, Times Higher Education Supplement, 16 August 2007.

Arthur MJP.
Opportunities knock, Times Higher Education, 3 July 2008.

Arthur MJP.
A personal view – We need to keep some selectivity in funding to ensure a critical mass of 'world-leading' research in our universities, Times Higher Education, 15 January 2009.

Arthur MJP, Piatt W.
View from the top: RAE puts recovery at risk, Research Fortnight, 18 March 2009.